Treatment extends life for men with prostate cancer

June 1, 2014
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

A new treatment has been shown to extend the lifespans of men with advanced prostate cancer by as much as one year, researchers said Sunday.

The study involved 790 men who were diagnosed with , meaning the disease had spread beyond the prostate.

By adding the chemotherapy drug docetaxel to standard , known as (ADT), fewer patients died and many lived longer.

After 29 months, 136 men had died in the ADT alone group and 101 in the combination group.

The median, or midpoint, overall survival for the ADT group was 44 months, while those who also received docetaxel lived 57.6 months.

ADT is an effective therapy but eventually most patients become resistant to it, allowing the cancer to spread.

Some 30,000 men die of hormone-resistant prostate cancer each year in the United States.

"Hormone has been a standard treatment for prostate cancer since the 1950s," said lead study author Christopher Sweeney of the Dana Farber Cancer Institute in Boston, Massachusetts.

"This is the first study to identify a strategy that prolongs survival in newly diagnosed metastatic ," he added, describing the benefit as "substantial."

The research was presented at the American Society of Clinical Oncology annual conference.

"These results demonstrate how we can use 'old tools' in new, more powerful ways to improve and extend patients' lives," said ASCO president Clifford Hudis.

Explore further: Study shows benefits for men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy

Related Stories

Study shows benefits for men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy

December 6, 2013
Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to ...

ASCO: No benefit for immediate ADT after PSA-only relapse

May 22, 2014
(HealthDay)—For men with a prostate-specific antigen (PSA)-only-based relapse after prostate surgery or radiation therapy, there seems to be little or no survival benefit for immediate initiation of androgen deprivation ...

Radiation for prostate cancer linked to secondary cancers, study finds

May 30, 2014
Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan Comprehensive Cancer Center.

Radiotherapy plus hormone therapy cuts prostate cancer death in half, shows long-term study

January 30, 2014
Combination treatment more than halves mortality rates for prostate cancer, reports Norwegian health journal Dagens Medisin.

Primary androgen deprivation therapy ineffective for most men with early prostate cancer

March 17, 2014
A study of more than 15,000 men with early stage prostate cancer finds that those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received ...

Patients receiving ADT should be counseled to improve mental and emotional well-being

January 23, 2014
A new study published in the Journal of Urology reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, although there ...

Recommended for you

Scientists develop a new model for glioblastoma using gene-edited organoids

April 24, 2018
Glioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It's virtually impossible to observe how these tumors operate in their natural environment and animal models don't ...

Experimental arthritis drug prevents stem cell transplant complication

April 24, 2018
An investigational drug in clinical trials for rheumatoid arthritis prevents a common, life-threatening side effect of stem cell transplants, new research from Washington University School of Medicine in St. Louis shows. ...

Changes in breast tissue increase cancer risk for older women

April 24, 2018
Researchers in Norway, Switzerland, and the United States have identified age-related differences in breast tissue that contribute to older women's increased risk of developing breast cancer. The findings, published April ...

Targeting molecules called miR-200s and ADAR2 could prevent tumor metastasis in patients with colorectal cancer

April 24, 2018
Colorectal cancer is the third most common cancer worldwide and the third-leading cause of cancer-related deaths. The main cause of death in patients with colorectal cancer is liver metastasis, with nearly 70% of patients ...

Research shows possible new target for immunotherapy for solid tumors

April 24, 2018
Research from the University of Cincinnati (UC) reveals a potential new target to help T cells (white blood cells) infiltrate certain solid tumors.

Removing the enablers: Reducing number of tumor-supporting cells to fight neuroblastoma

April 24, 2018
Investigators at the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles provide preclinical evidence that the presence of tumor-associated macrophages—a type of immune cell—can negatively ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.